Condition
BPDCN clinical trials and research
As of November 12, 2026, Find a Trial lists 4 BPDCN clinical trials that are recruiting, at sites in 4 countries (most in United States (2), China (1), Australia (1)). 1 was first registered in the last 30 days. By phase: Phase 1/2 (2), Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1New in 30 days
- 4Countries
Newest BPDCN clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| CARCIK-CD123/33 cells for relapsed or refractory AML and BPDCN in children and adults | Phase 1/2 | Monza, MB and 1 other locations | Recruiting | Oct 16, 2026 |
| Adaptive dual-target CAR-T therapy for relapsed or refractory blood cancers | Phase 1/2 | Shenzhen, Guangdong | Recruiting | Apr 13, 2026 |
| Using Tagraxofusp to treat pediatric patients with relapsed or refractory blood cancers | Phase 1 | Los Angeles, California and 30 other locations | Recruiting | Jul 27, 2022 |
| CD123-CAR T-cell therapy for treating acute myeloid leukemia and related conditions | Phase 1 | Memphis, Tennessee and 1 other locations | Recruiting | Mar 24, 2020 |
All recruiting trials (4)
-
CARCIK-CD123/33 cells for relapsed or refractory AML and BPDCN in children and adults
This trial tests CARCIK-CD123/33 cell therapy to see if it is safe and feasible for people with relapsed or refractory AML or BPDCN, including kids and adults, before planned stem cell transplant.
-
Adaptive dual-target CAR-T therapy for relapsed or refractory blood cancers
This trial will test whether matching a patient's cancer markers to one of several dual-target CAR-T therapies can work and be safe for adults whose blood cancer has come back or not responded.
-
Using Tagraxofusp to treat pediatric patients with relapsed or refractory blood cancers
This study is testing a new drug called Tagraxofusp to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.
-
CD123-CAR T-cell therapy for treating acute myeloid leukemia and related conditions
This study is testing a new type of T-cell therapy to see if it can safely help young people with certain types of leukemia and related blood disorders.
Related topics
Quick answers
How many BPDCN clinical trials are recruiting right now?
4, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in United States (2 trials), China (1 trial), Australia (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 2, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.